Company: TXG
Filing Date: 2025-11-07
Form Type: 10-Q
Source: 0001628280-25-050332
Chunk: 6

Company: 10x Genomics, Inc.
Filing Date: 2025-11-07
Form: 10-Q
Item: Part I, Item 1
Chunk 6
---
,753)— (35,753)Other comprehensive income— — — — 462 462 Balance as of September 30, 2024121,039,868 $2 $2,140,789 $(1,418,019)$32 $722,804 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

6

10x Genomics, Inc.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

(In thousands)

Nine Months Ended September 30,20252024Operating activities:Net loss$(27,292)$(133,599)Adjustments to reconcile net loss to net cash provided by operating activities:Stock-based compensation expense83,899 108,209 Depreciation and amortization26,134 27,129 Amortization of right-of-use assets5,582 6,015 Fair value adjustments on contingent consideration1,135 — Asset and lease impairment charges814 2,454 Realized loss on marketable securities— 3 Other(1,360)571 Changes in operating assets and liabilities:Accounts receivable44,546 31,321 Other receivables(52,208)— Inventory22,371 (19,396)Prepaid expenses and other current assets642 696 Other noncurrent assets2,290 (1,850)Accounts payable3,292 10,044 Accrued compensation and other related benefits2,284 (75)Deferred revenue(648)8,142 Accrued expenses and other current liabilities(9,939)(17,135)Operating lease liability(7,590)(9,763)Other noncurrent liabilities1,321 646 Net cash provided by operating activities95,273 13,412 Investing activities:Purchases of intangible assets— (1,000)Asset acquisition, net(8,616)— Purchases of property and equipment(4,158)(9,677)Purchases of marketable securities(98,859)— Proceeds from sales of marketable securities— 3,856 Proceeds from maturities of marketable securities100,000 25,782 Net cash provided by (used in) investing activities(11,633)18,961 Financing activities:Issuance of common stock from exercise of stock options and employee stock purchase plan purchases4,561 6,397